<code id='D570DABA4A'></code><style id='D570DABA4A'></style>
    • <acronym id='D570DABA4A'></acronym>
      <center id='D570DABA4A'><center id='D570DABA4A'><tfoot id='D570DABA4A'></tfoot></center><abbr id='D570DABA4A'><dir id='D570DABA4A'><tfoot id='D570DABA4A'></tfoot><noframes id='D570DABA4A'>

    • <optgroup id='D570DABA4A'><strike id='D570DABA4A'><sup id='D570DABA4A'></sup></strike><code id='D570DABA4A'></code></optgroup>
        1. <b id='D570DABA4A'><label id='D570DABA4A'><select id='D570DABA4A'><dt id='D570DABA4A'><span id='D570DABA4A'></span></dt></select></label></b><u id='D570DABA4A'></u>
          <i id='D570DABA4A'><strike id='D570DABA4A'><tt id='D570DABA4A'><pre id='D570DABA4A'></pre></tt></strike></i>

          Home / explore / explore

          explore


          explore

          author:hotspot    Page View:29479
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In